- Home
- JYD vs ATXS Comparison
JYD vs ATXS Comparison
Compare JYD & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- ATXS
- Stock Information
- Founded
- JYD 2001
- ATXS 2008
- Country
- JYD China
- ATXS United States
- Employees
- JYD N/A
- ATXS N/A
- Industry
- JYD Oil Refining/Marketing
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- ATXS Health Care
- Exchange
- JYD Nasdaq
- ATXS Nasdaq
- Market Cap
- JYD 390.7M
- ATXS 401.2M
- IPO Year
- JYD 2023
- ATXS 2015
- Fundamental
- Price
- JYD $4.03
- ATXS $6.81
- Analyst Decision
- JYD
- ATXS Strong Buy
- Analyst Count
- JYD 0
- ATXS 6
- Target Price
- JYD N/A
- ATXS $25.67
- AVG Volume (30 Days)
- JYD 129.6K
- ATXS 237.1K
- Earning Date
- JYD 03-26-2025
- ATXS 03-03-2025
- Dividend Yield
- JYD N/A
- ATXS N/A
- EPS Growth
- JYD N/A
- ATXS N/A
- EPS
- JYD N/A
- ATXS N/A
- Revenue
- JYD $82,427,232.00
- ATXS N/A
- Revenue This Year
- JYD N/A
- ATXS N/A
- Revenue Next Year
- JYD N/A
- ATXS N/A
- P/E Ratio
- JYD N/A
- ATXS N/A
- Revenue Growth
- JYD 63.05
- ATXS N/A
- 52 Week Low
- JYD $0.42
- ATXS $6.64
- 52 Week High
- JYD $5.01
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- JYD 56.41
- ATXS 31.94
- Support Level
- JYD $3.55
- ATXS $6.77
- Resistance Level
- JYD $4.43
- ATXS $7.30
- Average True Range (ATR)
- JYD 0.44
- ATXS 0.30
- MACD
- JYD -0.07
- ATXS 0.02
- Stochastic Oscillator
- JYD 37.23
- ATXS 14.66
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is a end-to-end supply chain solution providers in China, with a focus on providing cross-border logistics services. It offers freight forwarding services, (ii) supply chain management, and (iii) other value-added services.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.